168 related articles for article (PubMed ID: 20536987)
1. Inhibitors in previously treated patients: a review of the literature.
Kempton CL
Haemophilia; 2010 May; 16(102):61-5. PubMed ID: 20536987
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
Peerlinck K; Hermans C
Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
[TBL] [Abstract][Full Text] [Related]
3. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.
Kempton CL; Soucie JM; Abshire TC
J Thromb Haemost; 2006 Dec; 4(12):2576-81. PubMed ID: 17002659
[TBL] [Abstract][Full Text] [Related]
4. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
5. Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis.
Calvez T; Laurian Y; Goudemand J
Blood; 2007 Aug; 110(3):1073-4; author reply 1074-5. PubMed ID: 17644742
[No Abstract] [Full Text] [Related]
6. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
7. Management of factor VIII inhibitors.
Acharya SS; DiMichele DM
Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of factor VIII in hemophilia.
Lacroix-Desmazes S; Dimitrov JD; Repesse Y
N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
[No Abstract] [Full Text] [Related]
9. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
Kaveri S; Gringeri A; Heisel-Kurth M; Kreuz W
Haemophilia; 2009 Mar; 15(2):587-91. PubMed ID: 19347997
[No Abstract] [Full Text] [Related]
10. Factor VIII inhibitors: Advances in basic and translational science.
Lai JD; Lillicrap D
Int J Lab Hematol; 2017 May; 39 Suppl 1():6-13. PubMed ID: 28447409
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
Lacroix-Desmazes S; Pratt KP
Front Immunol; 2020; 11():639386. PubMed ID: 33569066
[No Abstract] [Full Text] [Related]
12. The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
Leissinger CA
Am J Hematol; 2012 May; 87 Suppl 1():S23-6. PubMed ID: 22473571
[TBL] [Abstract][Full Text] [Related]
13. Summary report of the First International Conference on inhibitors in haemophilia A.
Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
[No Abstract] [Full Text] [Related]
14. Inhibitor development in patients with hemophilia: an overview.
Leissinger CA
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
[No Abstract] [Full Text] [Related]
15. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
Kallas A; Kuuse S; Maimets T; Pooga M
Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
[No Abstract] [Full Text] [Related]
17. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
Berntorp E
Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
[TBL] [Abstract][Full Text] [Related]
18. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
Santagostino E; Young G; Carcao M; Mannucci PM; Halimeh S; Austin S
Expert Rev Hematol; 2018 Feb; 11(2):87-97. PubMed ID: 29258406
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
[No Abstract] [Full Text] [Related]
20. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.
Zhang AH; Skupsky J; Scott DW
Clin Rev Allergy Immunol; 2009 Oct; 37(2):114-24. PubMed ID: 19199081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
